Greenland Mines (NASDAQ: GRML) is executing a strategic transformation, announcing a series of corporate milestones that underscore its transition into a focused rare earths and critical minerals company. The company plans to spin off its biotechnology division in the fourth quarter of 2026, a move that will allow it to concentrate on its mining assets, including the Sarfartoq neodymium-praseodymium (NdPr) rare earths project and the Skaergaard palladium-gold-platinum project.
Nasdaq has formally approved the company's application relating to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements. This approval removes regulatory overhang and paves the way for the company's strategic initiatives. The acquisition of the Sarfartoq project was completed on Sept. 1 following approval by the Government of Greenland, marking a significant step in securing a domestic source of critical rare earths outside China.
An independent S-K 1300 Initial Assessment for the ST1 deposit at Sarfartoq estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. The project is expected to produce neodymium-praseodymium oxide, a key material for permanent magnets used in electric vehicles and wind turbines. According to the company, planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years. This positions Greenland Mines to become a major player in the non-Chinese rare earth supply chain.
In tandem with these operational advancements, Greenland Mines is reshaping its board. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining the board. This change brings fresh expertise as the company advances the Sarfartoq and Skaergaard projects.
The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. It also aims to advance its broader North Atlantic Critical Metals Corridor vision, linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, will allow Greenland Mines to unlock shareholder value and focus management's attention on the mining operations. For more details on the corporate milestones, visit the full press release.
As the global demand for critical minerals rises, Greenland Mines is positioning itself to capitalize on the shift toward secure supply chains. The completion of the Sarfartoq acquisition and the planned spin-off signal a clear commitment to becoming a leader in the rare earths sector. With the Nasdaq compliance resolved and a strengthened board, the company is set to execute its strategic vision.
